{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:14:26Z","timestamp":1789496066933,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s13555-024-01262-5","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T09:02:35Z","timestamp":1726477355000},"page":"2827-2839","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6220-2626","authenticated-orcid":false,"given":"Ian M.","family":"Catlett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2206-5476","authenticated-orcid":false,"given":"Lu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8149-5636","authenticated-orcid":false,"given":"Yanhua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1365-5207","authenticated-orcid":false,"given":"Subhashis","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3775-1778","authenticated-orcid":false,"given":"James G.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"key":"1262_CR1","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","volume":"2","author":"JE Greb","year":"2016","unstructured":"Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, et al. Psoriasis. Nat Rev Dis Prim. 2016;2:16082.","journal-title":"Nat Rev Dis Prim"},{"issue":"1","key":"1262_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1084\/jem.20050500","volume":"202","author":"FO Nestle","year":"2005","unstructured":"Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005;202(1):135\u201343.","journal-title":"J Exp Med"},{"issue":"3","key":"1262_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jaad.2009.05.042","volume":"62","author":"R Bissonnette","year":"2010","unstructured":"Bissonnette R, Papp K, Maari C, Yao Y, Robbie G, White WI, et al. A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. J Am Acad Dermatol. 2010;62(3):427\u201336.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1262_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","volume":"77","author":"KF Baker","year":"2018","unstructured":"Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn\u2019s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"502","key":"1262_CR5","doi-asserted-by":"publisher","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","volume":"11","author":"JR Burke","year":"2019","unstructured":"Burke JR, Cheng L, Gillooly KM, Strnad J, Zupa-Fernandez A, Catlett IM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11(502):eaaw1736.","journal-title":"Sci Transl Med"},{"issue":"5","key":"1262_CR6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"FO Nestle","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496\u2013509.","journal-title":"N Engl J Med"},{"issue":"3","key":"1262_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","volume":"140","author":"JE Hawkes","year":"2017","unstructured":"Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645\u201353.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"1262_CR8","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1038\/jid.2014.308","volume":"134","author":"E Witte","year":"2014","unstructured":"Witte E, Kokolakis G, Witte K, Philipp S, Doecke WD, Babel N, et al. IL-19 is a component of the pathogenetic IL-23\/IL-17 cascade in psoriasis. J Invest Dermatol. 2014;134(11):2757\u201367.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"1262_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/2040622318759282","volume":"9","author":"TC Chan","year":"2018","unstructured":"Chan TC, Hawkes JE, Krueger JG. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9(5):111\u20139.","journal-title":"Ther Adv Chronic Dis"},{"issue":"5","key":"1262_CR10","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.jaci.2008.02.026","volume":"121","author":"S Commins","year":"2008","unstructured":"Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol. 2008;121(5):1108\u201311.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1262_CR11","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1038\/s41598-019-41609-z","volume":"9","author":"RJ Konrad","year":"2019","unstructured":"Konrad RJ, Higgs RE, Rodgers GH, Ming W, Qian YW, Bivi N, et al. Assessment and clinical relevance of serum IL-19 levels in psoriasis and atopic dermatitis using a sensitive and specific novel immunoassay. Sci Rep. 2019;9(1):5211.","journal-title":"Sci Rep"},{"issue":"3","key":"1262_CR12","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","volume":"139","author":"F Kolbinger","year":"2017","unstructured":"Kolbinger F, Loesche C, Valentin MA, Jiang X, Cheng Y, Jarvis P, et al. \u03b2-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis. J Allergy Clin Immunol. 2017;139(3):923-32.e8.","journal-title":"J Allergy Clin Immunol"},{"key":"1262_CR13","doi-asserted-by":"publisher","first-page":"1356869","DOI":"10.3389\/fimmu.2024.1356869","volume":"15","author":"X Liu","year":"2024","unstructured":"Liu X, Chen L, Peng W, Deng H, Ni H, Tong H, et al. Th17\/Treg balance: the bloom and wane in the pathophysiology of sepsis. Front Immunol. 2024;15:1356869.","journal-title":"Front Immunol"},{"key":"1262_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.678355","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang S, Gang X, Yang S, Cui M, Sun L, Li Z, et al. The alterations in and the role of the Th17\/Treg balance in metabolic diseases. Front Immunol. 2021;12: 678355.","journal-title":"Front Immunol"},{"issue":"1","key":"1262_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12964-024-01505-0","volume":"22","author":"H Cui","year":"2024","unstructured":"Cui H, Wang N, Li H, Bian Y, Wen W, Kong X, et al. The dynamic shifts of IL-10-producing Th17 and IL-17-producing Treg in health and disease: a crosstalk between ancient \u201cYin-Yang\u201d theory and modern immunology. Cell Commun Signal. 2024;22(1):99.","journal-title":"Cell Commun Signal"},{"key":"1262_CR16","unstructured":"Sotyktu [package insert]. Princeton, NJ, USA: Bristol Myers Squibb, 2022."},{"key":"1262_CR17","unstructured":"Sotyktu [package insert]. Seoul, South Korea: BMS Korea Pharmaceuticals Co., 2023."},{"key":"1262_CR18","unstructured":"Sotyktu [product information]. Mulgrave, VIC, Australia: Bristol Myers Squibb Australia Pty. Ltd., 2022."},{"key":"1262_CR19","unstructured":"Sotyktu [product monograph]. Montreal, QC, Canada: Bristol Myers Squibb Canada Co., 2022."},{"key":"1262_CR20","unstructured":"Sotyktu [European summary of product characteristics]. Dublin, Ireland: Bristol Myers Squibb EEIG, 2023."},{"key":"1262_CR21","unstructured":"Sotyktu [package insert]. Tokyo, Japan: Bristol Myers Squibb K.K., 2022."},{"issue":"20","key":"1262_CR22","doi-asserted-by":"publisher","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","volume":"62","author":"ST Wrobleski","year":"2019","unstructured":"Wrobleski ST, Moslin R, Lin S, Zhang Y, Spergel S, Kempson J, et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019;62(20):8973\u201395.","journal-title":"J Med Chem"},{"issue":"6","key":"1262_CR23","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.jaci.2021.11.001","volume":"149","author":"IM Catlett","year":"2022","unstructured":"Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022;149(6):2010-20.e8.","journal-title":"J Allergy Clin Immunol"},{"issue":"14","key":"1262_CR24","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","volume":"379","author":"K Papp","year":"2018","unstructured":"Papp K, Gordon K, Thaci D, Morita A, Gooderham M, Foley P, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379(14):1313\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"1262_CR25","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","volume":"144","author":"JG Krueger","year":"2019","unstructured":"Krueger JG, Wharton KA Jr, Schlitt T, Suprun M, Torene RI, Jiang X, et al. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J Allergy Clin Immunol. 2019;144(3):750\u201363.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1262_CR26","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/bjd.20827","volume":"186","author":"R Oliver","year":"2022","unstructured":"Oliver R, Krueger JG, Glatt S, Vajjah P, Mistry C, Page M, et al. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Br J Dermatol. 2022;186(4):652\u201363.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1262_CR27","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","volume":"133","author":"H Sofen","year":"2014","unstructured":"Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014;133(4):1032\u201340.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1262_CR28","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379\u201390.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"1262_CR29","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1016\/j.jaci.2018.11.042","volume":"143","author":"S Visvanathan","year":"2019","unstructured":"Visvanathan S, Baum P, Vinisko R, Schmid R, Flack M, Lalovic B, et al. Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab. J Allergy Clin Immunol. 2019;143(6):2158\u201369.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1262_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.4049\/immunohorizons.2300003","volume":"7","author":"K Campbell","year":"2023","unstructured":"Campbell K, Li K, Yang F, Branigan P, Elloso MM, Benson J, et al. Guselkumab more effectively neutralizes psoriasis-associated histologic, transcriptomic, and clinical measures than ustekinumab. ImmunoHorizons. 2023;7(4):273\u201385.","journal-title":"ImmunoHorizons"},{"issue":"2","key":"1262_CR31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.36849\/JDD.2020.4645","volume":"19","author":"L Green","year":"2020","unstructured":"Green L, Weinberg JM, Menter A, Soung J, Lain E, Jacobson A. Clinical and molecular effects of interleukin-17 pathway blockade in psoriasis. J Drugs Dermatol. 2020;19(2):138\u201343.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1262_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Tha\u00e7i D, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29\u201339.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1262_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, program for evaluation of TYK2 inhibitor psoriasis second phase 3 trial. J Am Acad Dermatol. 2023;88(1):40\u201351.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01262-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01262-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01262-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T16:03:00Z","timestamp":1729008180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01262-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1262"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01262-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"28 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ian M. Catlett was an employee of and shareholder in Bristol Myers Squibb at the time of study conduct. Lu Gao and Yanhua Hu are employees of and shareholders in Bristol Myers Squibb. Subhashis Banerjee was an employee of and shareholder in Bristol Myers Squibb at the time of study conduct. James G. Krueger has received research grants from Bristol Myers Squibb during the conduct of the study, personal fees from AbbVie, Baxter, Biogen, Delenex, Kineta, Sanofi, Serono, and Xenoport, and research grants from Amgen, Dermira, Innovaderm, Janssen, Kadmon, Kyowa, Lilly, Merck, Novartis, Paraxel, and Pfizer outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This biomarker study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki. The protocol, amendments, and patient informed consent received appropriate approval by the institutional review board or independent ethics committee prior to the initiation of the trial at the study center. All patients provided written informed consent before any study-related procedures were performed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}